Mauna Kea Technologies SAS - Asset Resilience Ratio
Mauna Kea Technologies SAS (ALMKT) has an Asset Resilience Ratio of 5.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALMKT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Mauna Kea Technologies SAS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Mauna Kea Technologies SAS assets under control.
Liquid Assets Composition Over Time
This chart breaks down Mauna Kea Technologies SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Mauna Kea Technologies SAS total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €663.00K | 5.24% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €663.00K | 5.24% |
Asset Resilience Insights
- Limited Liquidity: Mauna Kea Technologies SAS maintains only 5.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Mauna Kea Technologies SAS Industry Peers by Asset Resilience Ratio
Compare Mauna Kea Technologies SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Mauna Kea Technologies SAS (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Mauna Kea Technologies SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.42% | €2.02 Million ≈ $2.36 Million |
€16.25 Million ≈ $18.99 Million |
+12.26pp |
| 2023-12-31 | 0.16% | €36.00K ≈ $42.09K |
€22.94 Million ≈ $26.82 Million |
+0.11pp |
| 2022-12-31 | 0.05% | €9.00K ≈ $10.52K |
€19.79 Million ≈ $23.14 Million |
-0.07pp |
| 2021-12-31 | 0.12% | €29.00K ≈ $33.90K |
€24.75 Million ≈ $28.94 Million |
-0.16pp |
| 2020-12-31 | 0.28% | €58.00K ≈ $67.81K |
€20.61 Million ≈ $24.09 Million |
+0.03pp |
| 2019-12-31 | 0.25% | €59.00K ≈ $68.98K |
€23.62 Million ≈ $27.62 Million |
-0.07pp |
| 2018-12-31 | 0.32% | €64.00K ≈ $74.82K |
€19.76 Million ≈ $23.10 Million |
-0.13pp |
| 2017-12-31 | 0.45% | €125.00K ≈ $146.14K |
€27.75 Million ≈ $32.44 Million |
-0.02pp |
| 2016-12-31 | 0.47% | €94.00K ≈ $109.90K |
€19.97 Million ≈ $23.35 Million |
+0.18pp |
| 2015-12-31 | 0.29% | €65.00K ≈ $75.99K |
€22.50 Million ≈ $26.31 Million |
-0.18pp |
| 2014-12-31 | 0.46% | €128.00K ≈ $149.65K |
€27.54 Million ≈ $32.19 Million |
-0.06pp |
| 2013-12-31 | 0.52% | €207.00K ≈ $242.00K |
€39.54 Million ≈ $46.23 Million |
+0.09pp |
| 2012-12-31 | 0.43% | €211.00K ≈ $246.68K |
€49.06 Million ≈ $57.35 Million |
-1.13pp |
| 2011-12-31 | 1.56% | €943.00K ≈ $1.10 Million |
€60.30 Million ≈ $70.50 Million |
-- |
About Mauna Kea Technologies SAS
Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more